Acorda Therapeutics (ACOR) Upgraded by BidaskClub to “Sell”

Share on StockTwits

Acorda Therapeutics (NASDAQ:ACOR) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued to investors on Tuesday, BidAskClub reports.

Other equities research analysts have also issued research reports about the company. HC Wainwright set a $33.00 price target on Acorda Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, January 23rd. Cowen reaffirmed a “buy” rating and set a $30.00 price target on shares of Acorda Therapeutics in a research note on Monday, January 7th. Zacks Investment Research raised Acorda Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, April 8th. Oppenheimer reaffirmed a “hold” rating on shares of Acorda Therapeutics in a research note on Tuesday, March 19th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and set a $20.00 price target on shares of Acorda Therapeutics in a research note on Friday, February 15th. Four equities research analysts have rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $22.56.

Shares of ACOR stock opened at $11.75 on Tuesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 4.30 and a quick ratio of 3.97. Acorda Therapeutics has a 12-month low of $9.58 and a 12-month high of $36.35. The stock has a market cap of $559.40 million, a price-to-earnings ratio of 6.46 and a beta of 1.34.

Acorda Therapeutics (NASDAQ:ACOR) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.07) by $0.51. Acorda Therapeutics had a positive return on equity of 9.34% and a negative net margin of 1.40%. The firm had revenue of $44.14 million during the quarter, compared to analyst estimates of $35.14 million. During the same quarter in the previous year, the company posted $0.14 earnings per share. The company’s revenue was down 58.4% compared to the same quarter last year. Equities research analysts anticipate that Acorda Therapeutics will post -4.43 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc lifted its stake in shares of Acorda Therapeutics by 11.3% in the 3rd quarter. Vanguard Group Inc now owns 5,384,536 shares of the biopharmaceutical company’s stock valued at $105,806,000 after acquiring an additional 545,689 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Acorda Therapeutics by 11.3% in the 3rd quarter. Vanguard Group Inc. now owns 5,384,536 shares of the biopharmaceutical company’s stock valued at $105,806,000 after acquiring an additional 545,689 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Acorda Therapeutics by 0.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,903,093 shares of the biopharmaceutical company’s stock valued at $45,229,000 after acquiring an additional 10,554 shares during the last quarter. Norges Bank bought a new stake in shares of Acorda Therapeutics in the 4th quarter valued at about $14,675,000. Finally, Acadian Asset Management LLC lifted its stake in shares of Acorda Therapeutics by 28.2% in the 4th quarter. Acadian Asset Management LLC now owns 584,747 shares of the biopharmaceutical company’s stock valued at $9,113,000 after acquiring an additional 128,760 shares during the last quarter.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.

Featured Story: Trading Options- What is a Strangle?

Analyst Recommendations for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.